New pill combo offers hope for kids with tough cancers
NCT ID NCT06465199
Summary
This study is testing a new combination of two oral drugs, AMXT 1501 and eflornithine (DFMO), for children and young adults with certain hard-to-treat cancers that have come back or not responded to standard treatments. The first part of the study aims to find the safest and most effective dose. The second part will compare the two-drug combination to DFMO alone to see which is better at keeping the cancer from growing or coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Arkansas Children's Hospital
RECRUITINGLittle Rock, Arkansas, 72202, United States
Contact
Contact Email: •••••@•••••
-
Children's Medical Center
RECRUITINGDallas, Texas, 75235, United States
Contact Email: •••••@•••••
Contact
-
Connecticut Children's Hospital
RECRUITINGHartford, Connecticut, 06106, United States
Contact Email: •••••@•••••
Contact
-
Kapiolani Medical Center for Women and Children
RECRUITINGHonolulu, Hawaii, 96813, United States
Contact Email: •••••@•••••
Contact
-
Penn State Milton S. Hershey Medical Center and Children's Hospital
RECRUITINGHershey, Pennsylvania, 17033, United States
Contact Email: •••••@•••••
Contact
-
St. Joseph's Children's Hospital
RECRUITINGTampa, Florida, 33614, United States
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.